Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

This study found that generic quality of life questionnaires, like the SF-36 and DLQI, are not sensitive enough to detect differences in health-related quality of life between patients with varying severity of alopecia areata.

In this study, researchers reported that treating alopecia areata patients with ritlecitinib led to progressive improvements in emotional symptoms and activity limitations over 48 weeks, though the post hoc analysis and trial setting suggest caution in interpreting the findings for broader populations.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.